ClinicalTrials.gg
RecruitingNCT07548983Updated Oct 5, 2026

Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation

A Phase 1 interventional study of Allogeneic Hematopoietic Stem Cell Transplantation and Azacitidine in Acute Myeloid Leukemia, sponsored by OHSU Knight Cancer Institute. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by OHSU Knight Cancer Institute · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.
Updated Oct 5, 2026Eligibility revisedPrimary outcomes revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 214 studies testing azacitidine in Leukemia, Myeloid, Acute — 72 open to participants now, 91 under way, 11 of them phase 3. Azacitidine · Leukemia, Myeloid, Acute.

Planned enrollment
123rd of 211
40 · median 50
Started
2026
with 25 others
Phase 1
41 of 214
10 open now
Primary completion
2027-12
later than 46 of 90 live
Registered
198th of 214
by date

Among the 214 studies testing azacitidine in Leukemia, Myeloid, Acute, this one is the 123rd largest by planned enrollment of the 211 interventional ones that give a count, is one of 26 that started in 2026, is one of 41 in phase 1, reaches primary completion later than 46 of the 90 other live ones, and was the 198th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

72 of the 214 studies testing azacitidine in Leukemia, Myeloid, Acute are open now, in 12 countries. Recruiting first, the newest first:

66 more — sign in →

By country, each count listing its studies:

All 72 open studies →

About azacitidine

Azacitidine: first FDA approval 2004 (VIDAZA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 214 studies testing azacitidine in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

This phase I trial studies the side effects and best dose of ruxolitinib (Rux) therapy alone (monotherapy) followed by Rux plus azacitidine (AZA) maintenance therapy and to see how well it works in treating patients with acute myeloid leukemia (AML) who are undergoing reduced intensity allogeneic hematopoietic stem cell transplantation (alloHSCT). AlloHSCT provides the only chance for cure for many patients with AML. AlloHSCT is a procedure in which a person receives blood-forming stem cells (cells from which all blood cells develop) from a genetically similar, but not identical, donor. This is often a sister or brother, but could be an unrelated donor. One of the common reasons for death after an alloHSCT is graft versus host disease (GVHD), which occurs when the transplanted cells from the donor attacks the recipient's normal cells. Ruxolitinib is in a class of medications called kinase inhibitors. It works to treat GVHD by blocking the signals of the cells that cause GVHD. Azacitidine is in a class of medications called demethylation agents. It works by helping the bone marrow to produce normal blood cells and by killing abnormal cells in the bone marrow. Giving Rux after the transplant may stop GVHD from occurring. Maintenance therapy with AZA, may help prevent or delay cancer from coming back. Giving Rux monotherapy followed by Rux plus AZA maintenance therapy may be safe, tolerable, and/or effective in treating patients with AML who are undergoing alloHSCT.

Read the detailed description

PRIMARY OBJECTIVE:

I. To evaluate the safety and tolerability of Rux monotherapy (part A) and Rux plus AZA maintenance therapy (part B) following alloHSCT in AML patients.

SECONDARY OBJECTIVES:

I. To evaluate the feasibility of Rux plus AZA maintenance. II. To evaluate the effect on measurable residual disease (MRD) of Rux plus AZA maintenance.

III. To evaluate the impact of post-alloHSCT Rux on neutrophil engraftment. IV. To evaluate the impact of post-alloHSCT Rux on platelet engraftment. V. To evaluate the frequency and timing of disease relapse after alloHSCT when treated with Rux +/- AZA maintenance.

VI. To evaluate risk of post alloHSCT acute graft versus host disease (aGVHD) when treated with Rux +/- AZA maintenance.

VII. To evaluate risk of post alloHSCT chronic graft versus host disease (cGVHD) when treated with Rux +/- AZA maintenance.

VIII. To evaluate post alloHSCT survival in the absence of GVHD and disease relapse when treated with Rux +/- AZA maintenance.

IX. To evaluate the rate of post alloHSCT early infection when treated with Rux +/- AZA maintenance.

X. To evaluate overall survival after alloHSCT and treatment with Rux +/- AZA maintenance.

XI. To overall the effect on quality of life (QoL) of post alloHSCT Rux +/- AZA maintenance.

EXPLORATORY OBJECTIVES:

I. To evaluate the impact of pre transplant disease characteristics on treatment outcomes.

II. To evaluate the impact of MRD on treatment outcomes. III. To explore biomarkers associated with treatment outcomes.

OUTLINE: This is a dose-escalation study of azacitidine in combination with fixed-dose cyclophosphamide, tacrolimus, mycophenolate mofetil, and ruxolitinib.

PART A: Patients undergo standard of care (SOC) reduced intensity conditioning (RIC) or non-myeloablative (NMA) conditioning followed by alloHSCT on day 0 and receive cyclophosphamide intravenously (IV) over 1-2 hours on days +3 and +4, tacrolimus orally (PO) or IV daily on day + 5 and tapered per institutional protocol through day +180, and mycophenolate mofetil PO or IV three times daily (TID) on days +5 to +35 in the absence of disease progression or unacceptable toxicity. Staring on day +5, patients also receive ruxolitinib PO twice daily (BID) continuously and tapered through post-treatment day 28. Treatment with ruxolitinib continues through screening of part B in the absence of disease progression or unacceptable toxicity. Patients not eligible for Part B have ruxolitinib tapered starting no later than day +100.

PART B: Starting no earlier than day +35 and no later than day +100, patients receive ruxolitinib PO BID continuously and tapered through post-treatment day 28, as well as azacitidine IV on days 1-5 of each cycle. Cycles repeat every 28 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.

Additionally, patients undergo echocardiography (ECHO) or multigated acquisition scan (MUGA) during screening. Patients also undergo blood sample collection and bone marrow aspiration and biopsy throughout the study.

After completion of study treatment, patients are followed up every 3 months for the first year and every 6 months until 2 years.

03

Conditions studied

  • Acute Myeloid Leukemia
04

Who can participate

The criteria were revised on the registry on Oct 5, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • PART A: Willingness to provide written before any study-specific procedures or interventions are performed. For participants unable to independently provide consent, a legally authorized representative (LAR) must provide consent
  • PART A: Age ≥ 18 years, at the time of consent
  • PART A: All types and categories of AML, as defined by World Health Organization (WHO) 2022, excluding acute promyelocytic leukemia (APL)
  • PART A: In complete remission (CR) or complete remission with incomplete blood count recovery (CRi) after induction of remission for transition to transplant by European LeukemiaNet 2022 Risk Stratification (ELN 2022)
  • PART A: Planned with granulocyte colony-stimulating factor mobilized peripheral blood stem cells (PBSCs) and pre transplant conditioning disease status assessment of CR or CRi, as defined by ELN 2022 criteria
  • PART A: Patient is at high risk for relapse based on cytogenetics, MRD by next generation sequencing (NGS), and/or ELN 2022 definition of adverse risk disease per the opinion of the treating physician
  • PART A: Patients must have an unrelated PBSC donor meeting study donor selection requirements
  • PART A: Only RIC or NMA conditioning must be plan and patient is not a candidate for myeloablative conditioning (MAC). Post-transplant cyclophosphamide / tacrolimus / mycophenolate mofetil (PTCy/Tac/MMF) prophylaxis is planned with PTCy at 25 mg/kg/day on Day +3 and Day +4 post-HSCT

    • Permitted conditioning regimens (per institutional protocol)

      • Reduced-intensity conditioning:

        • Fludarabine/ melphalan

          • Dose reduction of melphalan to 100 mg/m\^2 rather than 140 mg/m\^2 are permitted at discretion of treating physician
      • Non-Myeloablative Conditioning:

        • Fludarabine/ busulfan/ total-body irradiation (TBI)
        • Fludarabine/ TBI
  • PART A: Backup graft donor (meeting study donor selection requirements) identified and ready for cases of graft failure
  • PART A: (ECOG) performance status (ECOG PS) ≤ 2
  • PART A: Direct ≤ 3 × (ULN) within 7 days prior to start of conditioning. Patients with leukemic involvement or Gilbert's Syndrome must have a direct bilirubin of ≤ 2 x ULN within 7 days of start of conditioning
  • PART A: > 30 mL/min, calculated by the Cockcroft-Gault formula or measured by 24-hour urine collection
  • PART A: Willingness to receive infusion of SOC blood products
  • PART A: Evidence of chronic virus (HBV) infection (i.e., hepatitis B virus surface antigen [HBsAg]-positive with undetectable or low HBV deoxyribonucleic acid [DNA]) in the absence of HBV therapy, or serologic evidence of a resolved prior HBV infection (i.e., HBsAg-negative and hepatitis B virus core antibody [anti-HBc-positive]) is permitted but patient must agree to appropriate institutional guideline prophylaxis
  • PART A: History of virus (HCV) infection is permitted given prior curative treatment or undetectable HCV viral load by serology or polymerase chain reaction (PCR) testing

    • Patients who are HCV antibody (Ab) seropositive but HCV ribonucleic acid (RNA) negative due to prior treatment or natural resolution are eligible
  • PART A: For persons of (PCBP), a negative pregnancy test within ≤ 7 days of start of conditioning
  • PART A: Ruxolitinib may have adverse effects on a fetus in utero. Furthermore, it is not known if either drug agent has transient adverse effects on the composition of sperm. PCBP and participants who produce viable sperm must be willing to comply with study requirements for starting at start of conditioning through 120 days after discontinuation of study treatment. Should a participant or participant's sexual partner become pregnant or suspect a pregnancy while participating in this study, the individual should inform their treating physician immediately
  • PART A: It is unknown whether ruxolitinib, or its metabolites, are excreted in human milk. Since many drugs are excreted in human milk, and because of the potential for serious adverse reactions in the nursing infant, patients must agree to not breast-feed for the entire 3 years of the study to be eligible for enrollment
  • PART B: (ANC) ≥ 1,000/μL, measured twice approximately 48 hours apart, within 7 days prior to C2D1, in the absence of granulocyte colony-stimulating factor (G-CSF) treatment during this 7-day period
  • PART B: count ≥ 50,000/μL, measured twice approximately 48 hours apart, within 7 days prior to C2D1, in the absence of platelet transfusions or growth factor therapies that increase platelet counts during this 7 day period
  • PART B: > 8 g/L within the 7 days prior to C2D1, regardless of transfusion support
  • PART B: Day +30 (+/- 5 days) chimerism of ≥ 70% donor CD3+ cells and 100% donor CD33+ cells
  • DONOR: Donor is willing and able to donate
  • DONOR: Unrelated donor with a 7/8 or 8/8 match at human leukocyte antigen (HLA)-A, -B, -C and -DRB1 at high resolution using DNA-based typing. Unrelated donor must be willing to donate peripheral blood stem cells
  • DONOR: Age 18-35 at the time of workup request for PBSC donation
  • DONOR: Meet the donor registries' medical suitability requirements for PBSC donation
  • DONOR: Must undergo screening, testing, and determination of eligibility according to current Food and Drug Administration (FDA) requirements as defined in 21 Code of Federal Regulations (CFR) 1271 Subpart C and applicable guidance documents. Donors will be tested using kits that are FDA licensed, approved, or cleared for human cell and tissue/tissue-product donor screening. Sample testing will be performed at Clinical Laboratory Improvement Amendments (CLIA) certified laboratories
  • DONOR: Must agree to donate PBSC
  • DONOR: Must have the ability to give informed consent according to standard (non study) informed consent according to applicable donor regulatory requirements

Exclusion criteria

Exclusion Criteria:

  • PART A: Patients with active central nervous system (CNS) involvement with AML. Prior diagnosis of CNS involvement of AML will be allowed if curatively treated
  • PART A: Patients with malabsorption syndrome or other condition that precludes oral route of drug administration
  • PART A: Patients with prior intolerance to any of the interventional study drugs or component of the formulations
  • PART A: Patients with prior failure of treatment with ruxolitinib
  • PART A: Patients with history of any other within the 5 years prior to screening, with the exception of the following:

    • Adequately treated in situ carcinoma of the cervix uteri or carcinoma in situ of breast;
    • Basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin;
    • Previous non-hematologic malignancy that has been successfully treated with curative intent (i.e., confined and surgically resected or treated with other modalities);
    • Myelodysplastic syndrome (MDS) or myeloproliferative neoplasm (only allowed if it transformed to AML and AML should be the indication for marrow transplantation)
  • PART A: Patients with (EF) \< 40% and patients with (NYHA) grade III or IV heart failure
  • PART A: Patients with history of pulmonary embolism (PE) or myocardial infarction (MI) within the 6 months prior to cycle 1 day 1 (C1D1). Treated deep vein thromboses (DVTs) are allowed
  • PART A: Patients with known history of stroke (including intracranial hemorrhage) within 60 days prior to start of conditioning
  • PART A: Patients administered therapy with an agent, a known JAK1/2 inhibitor (with the exception of ruxolitinib), or a SOC anti-cancer therapy, including chemotherapy and radiotherapy, within 5 half lives prior to C1D1, or per institutional practice
  • PART A: Patients administered therapy with a biologic agent (e.g., a monoclonal antibody) for anti-neoplastic intent within 30 days prior to C1D1, or per the institutional practice
  • PART A: Patients administered moderate or strong inhibitors or inducers without full washout (5 half-lives) prior to start of study intervention, or at the discretion of pharmacy services and the principal investigator (PI)
  • PART A: Patients with known liver disease defined as ongoing drug-induced liver injury, alcoholic liver disease, non alcoholic steatohepatitis, primary biliary cirrhosis, extrahepatic obstruction caused by cholelithiasis, cirrhosis of the liver, portal hypertension, or history of hepatitis
  • PART A: Patients with known (HIV) infection. HIV infection, even when controlled with combination antiretroviral therapy, is not allowed due to increased risk of lethal infections associated with marrow-suppressive therapy. Studies in participants under combination antiretroviral therapy may be undertaken at a later date
  • PART A: Patients with history of active tuberculosis (TB)
  • PART A: Patients with known active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection

    • Subjects with confirmed SARS-CoV-2 infection must be screen failed and may only rescreen after they meet institutional SARS-CoV-2 infection viral clearance criteria
  • PART A: Patients with evidence of clinically significant systemic infection
  • PART A: Patients with clinically significant coagulation abnormality defined by (INR) > 1.5
  • PART A: Patients with recent significant medical interventions, such as major surgery within 28 days of C1D1. Standard of care procedures for patients with hematologic malignancies, such as and lumbar punctures, are allowed
  • PART A: Patients with psychiatric illness/social situation that would limit compliance with the study
  • PART A: Patients with history of clinically significant medical condition(s) (including comorbidities) and no other reason, per the determination of the investigator, which could interfere with the patient's adherence to the study protocol or would make the patient an unsuitable candidate to receive study drugs
  • PART B: Patients with evidence of primary graft failure (PGF) or secondary graft failure (SGF) while enrolled on Part A or SGF during screening for Part B
  • PART B: Patients who experienced a dose limiting toxicity (DLT) in Part A
  • PART B: Patients administered an investigational agent, a known JAK1/2 inhibitor (with the exception of ruxolitinib), or SOC chemotherapy or radiotherapy within 5 half-lives of C2D1, or per institutional practice
  • PART B: Patients administered a biologic of anti-neoplastic intent within 30 days of C2D1, or per institutional practice
  • PART B: Patients with a plan for other maintenance therapy outside of this trial, including a FLT3-ITD inhibitor
  • PART B: Patients with evidence of clinically significant, uncontrolled systemic infection
  • PART B: Patients with Mount Sinai Acute International Consortium (MAGIC) grade II or greater active aGVHD
  • PART B: Patients with ongoing or planned therapy with prednisone equivalent of ≥ 10 mg daily for GVHD treatment or other illness
  • PART B: Patients with newly diagnosed psychiatric illness or new social situation that would limit compliance with the study
  • PART B: Patients with new or recent history of clinically significant medical condition(s) (including comorbidities) or any other reason, per the determination of the investigator, which could interfere with the patient's adherence to the study protocol or would make the patient an unsuitable candidate to receive study drugs
  • DONOR: Recipient has evidence of donor-specific HLA antibody (DSA). If recipient is positive for HLA antibodies against a mismatched HLA in the selected donor, defined as the presence of DSA to any mismatched HLA allele/antigen at any of the following loci (HLA-A, -B, -C, -DRB1, DRB3, DRB4, DRB5, -DQA1, - DQB1, -DPA1, -DPB1) with mean fluorescence intensity (MFI) > 3000 by microarray-based single antigen bead testing, the donor will be excluded. In patients receiving red blood cell or transfusions, DSA evaluation should be performed prior to donor mobilization and initiation of recipient preparative regimen whenever possible
  • DONOR: Donors with positive coronavirus disease 2019 (COVID-19) testing results (confirmed by PCR) within 72 hours (hr) of stem cell collection
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Treatment (ruxolitinib, azacitidine)

    See Detailed Description.

    Procedure: Allogeneic Hematopoietic Stem Cell Transplantation · Drug: Azacitidine · Procedure: Biospecimen Collection · Procedure: Bone Marrow Aspiration · Procedure: Bone Marrow Biopsy · Drug: Cyclophosphamide · Procedure: Echocardiography Test · Other: Electronic Health Record Review · Procedure: Multigated Acquisition Scan · Drug: Mycophenolate Mofetil · Other: Reduced-Intensity Transplant Conditioning Procedure · Drug: Ruxolitinib · Other: Survey Administration · Drug: Tacrolimus

Interventions

  • ProcedureAllogeneic Hematopoietic Stem Cell Transplantation

    Undergo alloHSCT

    Also known as: Allogeneic, Allogeneic Hematopoietic Cell Transplantation, Allogeneic Stem Cell Transplantation, HSC, HSCT, Stem Cell Transplantation, Allogeneic

  • Given IV

    Also known as: 5 AZC, 5-AC, 5-Azacitidine, 5-Azacytidine, 5-AZC, Azacytidine, Azacytidine, 5-, Ladakamycin, Mylosar, U-18496, Vidaza

  • ProcedureBiospecimen Collection

    Undergo blood sample collection

    Also known as: Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen Collection

  • ProcedureBone Marrow Aspiration

    Undergo bone marrow aspiration

  • ProcedureBone Marrow Biopsy

    Undergo bone marrow biopsy

    Also known as: Biopsy of Bone Marrow, Biopsy, Bone Marrow

  • Given IV

    Also known as: (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B 518, B-518, B518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Frindovyx, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR 138719, WR- 138719, WR-138719, WR138719

  • ProcedureEchocardiography Test

    Undergo ECHO

    Also known as: EC, Echocardiography

  • OtherElectronic Health Record Review

    Ancillary studies

  • ProcedureMultigated Acquisition Scan

    Undergo MUGA

    Also known as: Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning

  • DrugMycophenolic AcidStudies of Mycophenolic AcidMycophenolic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given PO or IV

    Also known as: CellCept, MMF, Myhibbin

  • OtherReduced-Intensity Transplant Conditioning Procedure

    Undergo SOC RIC or NMA conditioning

    Also known as: Non-Myeloablative Conditioning, Reduced Intensity Conditioning, Reduced Intensity Conditioning/Reduced Toxicity Conditioning

  • Given PO

    Also known as: INCB 018424, INCB-018424, INCB-18424, INCB18424, Oral JAK Inhibitor INCB18424

  • OtherSurvey Administration

    Ancillary studies

  • Given PO or IV

    Also known as: FK 506, FK-506, FK506, Fujimycin, Hecoria, Prograf, Protopic, Tacforius

06

What researchers measure

Primary outcomes

  1. Incidence of dose limiting toxicities (DLTs)

    Will determine the safety and tolerability of ruxolitinib monotherapy (part A) and ruxolitinib plus azacitidine therapy (part B). DLTs will be used to identify a maximum tolerated dose. Dose levels will either be de-escalated, escalated, or retained-according to pre calculated Bayesian Optimal Interval decision rules.

    Time frame: From cycle 1 day 1 (i.e., day +5 post-transplant) to end of cycle 2 (Cycle length = 28 days)

  2. Incidence of grade 3+ treatment-related adverse events (TRAEs) (Part B)

    TRAEs of grade 3 and higher experienced during treatment with the doublet of ruxolitinib + azacitidine will be reported (with frequencies and percentages) as a co-primary endpoint. TRAEs are defined as adverse events that are definitely or possibly attributable to study treatment. Will be assessed using Common Terminology Criteria for Adverse Events version 5.0, where adverse events are assessed on a scale of 1-5, with higher scores indicating worse outcomes.

    Time frame: Up to 30 days after the end of cycle 9

Secondary outcomes

  1. Graft versus host disease (GVHD)-free, relapse-free survival

    Will be estimated by the Kaplan-Meier method, with estimates provided for the median time-to-event (with 95% log-log confidence interval \[CI\]) and event rates (and 95% log-log CIs) at landmark times like 3-, 6-, 12-, and 24-months post-allogeneic hematopoietic stem cell transplant (HSCT).

    Time frame: From date of transplant to disease relapse, grade III-IV acute (a) GVHD, chronic (c) GVHD requiring systemic immunosuppressive therapy, or death from any cause or last known alive (censored), whichever occurs earlier, assessed up to 2 years

  2. Overall survival

    Will be estimated by the Kaplan-Meier method, with estimates provided for the median time-to-event (with 95% log-log CI) and event rates (and 95% log-log CIs) at landmark times like 3-, 6-, 12-, and 24-months post-allogeneic HSCT.

    Time frame: From date of transplant to last known alive (censored) or death date, assessed up to 2 years

  3. Cumulative incidence of neutrophil engraftment

    Deaths in the absence of the event of interest will be considered as a competing risk. Cumulative incidence function (CIF) estimates will be provided with 95% CIs at landmark times (e.g., day +30, day +60, day +100) for each time-to-event endpoint with a competing risk.

    Time frame: From date of transplant to 30 days post-HSCT

  4. Cumulative incidence of platelet engraftment

    Deaths in the absence of the event of interest will be considered as a competing risk. CIF estimates will be provided with 95% CIs at landmark times (e.g., day +30, day +60, day +100) for each time-to-event endpoint with a competing risk.

    Time frame: From date of transplant to 100 days post-HSCT but prior to Part B

  5. Cumulative incidence of Blood and Marrow Transplant Clinical Trials Network grade 2-3 infections

    Deaths in the absence of the event of interest will be considered as a competing risk. CIF estimates will be provided with 95% CIs at landmark times (e.g., day +30, day +60, day +100) for each time-to-event endpoint with a competing risk.

    Time frame: From date of transplant to 100 days post-HSCT

  6. Cumulative incidence of grade ≥ II aGVHD

    Will be assessed using Mount Sinai Acute Graft Versus Host Disease International Consortium criteria. Deaths in the absence of the event of interest will be considered as a competing risk. CIF estimates will be provided with 95% CIs at landmark times (e.g., day +30, day +60, day +100) for each time-to-event endpoint with a competing risk.

    Time frame: From date of transplant to end of study, assessed up to 2 years

  7. Cumulative incidence of cGVHD requiring systemic immunosuppressive therapy

    Deaths in the absence of the event of interest will be considered as a competing risk. CIF estimates will be provided with 95% CIs at landmark times (e.g., day +30, day +60, day +100) for each time-to-event endpoint with a competing risk.

    Time frame: From day +100 post-HSCT to end of study, assessed up to 2 years

  8. Cumulative incidence of relapse

    Deaths in the absence of the event of interest will be considered as a competing risk. CIF estimates will be provided with 95% CIs at landmark times (e.g., day +30, day +60, day +100) for each time-to-event endpoint with a competing risk.

    Time frame: From date of transplant to end of study, assessed up to 2 years

  9. Percentage of part A participants enrolled on part B (Feasibility)

    Descriptive summaries of discrete data will present the sample size and the incidence as frequency count and percentage, with exact binomial 95% CI.

    Time frame: From part A screening (day -28 to day -5 pre-transplant) to part B screening (day +35 post-HSCT to day +100 post-HSCT) assessed up to 128 days

  10. Median time from transplant to part B enrollment (Feasibility)

    Descriptive summaries of continuous data will present mean and standard deviation, or median, interquartile range, and range, depending on the sample distribution of the continuous variable.

    Time frame: From part A screening (day -28 to day -5 pre-transplant) to part B screening (day +35 post-HSCT to day +100 post-HSCT) assessed up to 128 days

  11. Patient reported quality of life outcome measurements, using the FACT-BMT patient reported outcome questionnaires

    Descriptive summaries of discrete data will present the sample size and the incidence as frequency count and percentage, with exact binomial 95% CI.

    Time frame: From time of part A screening to 365 days post-HSCT

  12. Conversion rate of pre-transplant measurable residual disease (MRD) positive to negative

    Time frame: From pre-transplant MRD assessment date to 1 year on study treatment or end of therapy, whichever occurs later, assessed up to 2 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Dec 2027, 20 months after the start.

Of 307 non-industry phase 1 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 87. This study's planned 20 months is below that.

Counting every sponsor, half of 489 studies reached it within 49 months; a quarter within 31 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2026
First posted
Apr 23, 2026
StartActual
Apr 21, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 29, 2028
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
3 inclusion criteria edited, 1 removed; 1 exclusion criterion added
What changed in the criteria
Inclusion criteria
  • EditedDose reduction of melphalan to 100 mg/m\^2 rather than 140 mg/m\^2 are permitted at discretion of treating physician
  • ChangedBefore PART A: Karnofsky performance status (KPS) ≥ 50%Now PART A: Eastern Cooperative Oncology Group (ECOG) performance status (ECOG PS) ≤ 2
  • EditedPART A: It is unknown whether ruxolitinib, or its metabolites, are excreted in human milk. Since many drugs are excreted in human milk, and because of the potential for serious adverse reactions in the nursing infant, patients must agree to not breast-feed for the entire 23 years of the study to be eligible for enrollment
  • RemovedPART B: For PCBP, a negative pregnancy test within 72 hours prior to C2D1
Exclusion criteria
  • AddedPART A: Patients administered moderate or strong CYP3A4 inhibitors or inducers without full washout (5 half-lives) prior to start of study intervention, or at the discretion of pharmacy services and the principal investigator (PI)
Oct 5, 2026
Primary outcomes
2 time frame changed
What changed in the outcomes
  • Time frameIncidence of dose limiting toxicities (DLTs)From cycle 1 day 1 (day +5 post-transplant) to end of cycle 2 (Cycle length = 28 days) → From cycle 1 day 1 (i.e., day +5 post-transplant) to end of cycle 2 (Cycle length = 28 days)
  • Time frameIncidence of grade 3+ treatment-related adverse events (TRAEs) (Part B)Up to 30 days after last dose of study drug → Up to 30 days after the end of cycle 9
Oct 5, 2026
Secondary outcomes
1 time frame changed
What changed in the outcomes
  • Time frameCumulative incidence of platelet engraftmentFrom date of transplant to 100 days post-HSCT → From date of transplant to 100 days post-HSCT but prior to Part B
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Eligibility 3 inclusion criteria edited, 1 removed; 1 exclusion criterion added
    What changed in the criteria
    Inclusion criteria
    • EditedDose reduction of melphalan to 100 mg/m\^2 rather than 140 mg/m\^2 are permitted at discretion of treating physician
    • ChangedBefore PART A: Karnofsky performance status (KPS) ≥ 50%Now PART A: Eastern Cooperative Oncology Group (ECOG) performance status (ECOG PS) ≤ 2
    • EditedPART A: It is unknown whether ruxolitinib, or its metabolites, are excreted in human milk. Since many drugs are excreted in human milk, and because of the potential for serious adverse reactions in the nursing infant, patients must agree to not breast-feed for the entire 23 years of the study to be eligible for enrollment
    • RemovedPART B: For PCBP, a negative pregnancy test within 72 hours prior to C2D1
    Exclusion criteria
    • AddedPART A: Patients administered moderate or strong CYP3A4 inhibitors or inducers without full washout (5 half-lives) prior to start of study intervention, or at the discretion of pharmacy services and the principal investigator (PI)
    Primary outcomes 2 time frame changed
    What changed in the outcomes
    • Time frameIncidence of dose limiting toxicities (DLTs)From cycle 1 day 1 (day +5 post-transplant) to end of cycle 2 (Cycle length = 28 days) → From cycle 1 day 1 (i.e., day +5 post-transplant) to end of cycle 2 (Cycle length = 28 days)
    • Time frameIncidence of grade 3+ treatment-related adverse events (TRAEs) (Part B)Up to 30 days after last dose of study drug → Up to 30 days after the end of cycle 9
    Secondary outcomes 1 time frame changed
    What changed in the outcomes
    • Time frameCumulative incidence of platelet engraftmentFrom date of transplant to 100 days post-HSCT → From date of transplant to 100 days post-HSCT but prior to Part B
    + 3 other changes: verification date, description and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07548983
Responsible party
Jennifer Saultz (Principal Investigator, OHSU Knight Cancer Institute) — Principal investigator
First posted
Apr 23, 2026
Start date
Apr 21, 2026
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 29, 2028 (estimated)
Last update
Oct 5, 2026

Study contacts

Jennifer N Saultz
principal investigator · OHSU Knight Cancer Institute

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Azacitidine · Ruxolitinib

Start the discussion